Artivion, Inc. Revises Earnings Guidance for the Full Year 2023
August 03, 2023 at 04:11 pm
Share
Artivion, Inc. revised earnings guidance for the full year 2023. For the year, the company raising its revenue guidance range and now expects to achieve constant currency revenue growth of between 10% and 12%, compared to the previous range of 9% and 12%, for the full year 2023 compared to 2022. The Company expects revenues to be in a range of $342.0 million and $350.0 million, compared to the previous range of $337.0 million and $348.0 million.
Artivion, Inc. is a medical device company engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease, heart valve disease, aortic aneurysms, and dissections. The Company's segments include Medical Devices and Preservation Services. The Medical Devices segment includes sales of aortic stent grafts, surgical sealants, and On-X. The Preservation Services segment includes services for the preservation of cardiac and vascular implantable human tissues. It has four product families: aortic stent grafts, surgical sealants, On-X mechanical heart valves and related surgical products, and implantable cardiac and vascular human tissues. Aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Surgical sealants include BioGlue Surgical Adhesive products. It also sells or distributes PhotoFix bovine surgical patches.
ARTIVION, INC. 
